Skip to main content
SpringerLink
Log in

Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 533 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10–30.

    Article  PubMed  Google Scholar 

  2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351(18):1860–73.

    Article  PubMed  CAS  Google Scholar 

  3. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78(1):21–33.

    Article  PubMed  Google Scholar 

  4. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV,. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004;79(7):867–74.

    Article  PubMed  CAS  Google Scholar 

  5. Rogerson G. Thalidomide and congenital abnormalities. Lancet 1962;1:691.

    Google Scholar 

  6. Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Ther 1965;6:298–302.

    Google Scholar 

  7. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 1965;6(3):292–297.

    PubMed  CAS  Google Scholar 

  8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082–5.

    Article  PubMed  Google Scholar 

  9. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64(6):971–8.

    Article  PubMed  CAS  Google Scholar 

  10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–6.

    Article  PubMed  CAS  Google Scholar 

  11. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333(26):1757–63.

    Article  PubMed  CAS  Google Scholar 

  12. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565–71.

    Article  PubMed  CAS  Google Scholar 

  13. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc 2004;79(7):899–903.

    Article  PubMed  CAS  Google Scholar 

  14. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F,. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100(9):3063–7.

    Article  PubMed  CAS  Google Scholar 

  15. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD,. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269–76.

    Article  PubMed  CAS  Google Scholar 

  16. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314–22.

    Article  PubMed  CAS  Google Scholar 

  17. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT,. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2943–50.

    PubMed  CAS  Google Scholar 

  18. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y-T,. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210–216.

    Article  PubMed  CAS  Google Scholar 

  19. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99(12):4525–30.

    Article  PubMed  CAS  Google Scholar 

  20. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001;7(11):3349–55.

    PubMed  CAS  Google Scholar 

  21. Payvandi F W u L H aley M Schafer PH, Zhang LH, Chen RS, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 2004;230(2):81–8.

    Article  PubMed  CAS  Google Scholar 

  22. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210–6.

    Article  PubMed  CAS  Google Scholar 

  23. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103(5):1787–90.

    Article  PubMed  CAS  Google Scholar 

  24. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT,. et al Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950–61.

    PubMed  CAS  Google Scholar 

  25. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69(1–2):56–63.

    Article  PubMed  CAS  Google Scholar 

  26. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17(1):41–4.

    Article  PubMed  CAS  Google Scholar 

  27. Dimopoulos MA, Weber D, Chen C, Spencer A, Niesvizky R, Attal M, et al. Evaluating oral lenalidomide (Revlimid-) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2005;90(S2):160.

    Google Scholar 

  28. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S,. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. ASH Annual Meeting Abstracts 2006;108(11):798.

    Google Scholar 

  29. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):LBA8025-.

    Google Scholar 

  30. Niesvizky R, Jayabalan DS, Furst JR, Cho HJ, Pearse RN, Zafar F, et al. Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006;24(18_suppl):7545-.

    Google Scholar 

  31. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melpha-lan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367(9513):825–31.

    Article  PubMed  CAS  Google Scholar 

  32. Facon T, Mary J, Harousseau J, Huguet F, Berthou C, Grosbois B, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006;24(18_suppl):1-.

    Google Scholar 

  33. Palumbo A, Falco P, Benevolo G, Canepa L, D'Ardia S, Gozzetti A, et al. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006;24(18_suppl):7518-.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, Rochester, MN, USA

    Shaji Kumar

Authors
  1. Shaji Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kumar, S. (2008). Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_18

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation